HGH Fragment 176-191

HGH Fragment 176-191 is the name given to a short stretch of the human growth hormone (hGH) molecule: the final sixteen amino acids at its C-terminal end. Human growth hormone is a 191-amino-acid protein secreted by the anterior pituitary gland. Rather than working with the whole hormone, researchers in the 1970s and 1980s began cutting it into pieces to find out which regions carried which biological activities. The C-terminal region emerged from that work as the part associated with effects on fat metabolism.

The logic behind the fragment is straightforward. Intact growth hormone does several different things at once: it stimulates hepatic production of IGF-1 (the mediator of most of its growth-promoting actions), it antagonizes insulin, and it promotes the breakdown of stored triglycerides in adipose tissue. If those activities could be separated, a molecule carrying only the fat-related activity would, in theory, avoid the growth signaling and the glucose problems that limit growth hormone itself. HGH Fragment 176-191 was the candidate built on that premise.

It is important to be precise about what the fragment is not. It is not growth hormone, it is not a growth hormone releasing peptide, and it is not a secretagogue. It does not cause the pituitary to release more hormone, and in the published preclinical work it did not compete for the growth hormone receptor. That is the whole point of the design, and it is also why the fragment belongs in a different conceptual category from compounds such as sermorelin, ipamorelin or CJC-1295.

Here is the basic chemical identity of the native sequence, which is useful when comparing specification sheets:

Everything that follows in this guide rests on one structural detail that is widely glossed over online, and that is the subject of the next section.

No, not literally, although the two names are used interchangeably almost everywhere. This distinction matters more than it might appear, because it determines which published studies can legitimately be cited in support of which molecule.

In the peer-reviewed literature, AOD-9604 is consistently defined as the hGH fragment spanning residues 177 to 191 with an additional tyrosine residue added at the N-terminus. Both the pooled human safety analysis by Stier and colleagues and the anti-doping analytical work by Cox and colleagues describe it in exactly those terms. Written out, AOD-9604 is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe.

Now compare that with the native hormone. In human growth hormone, residue 176 is a phenylalanine, and residues 177 to 191 are Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. So the genuine 176-191 fragment begins with phenylalanine, while AOD-9604 begins with tyrosine. They are both sixteen residues long and they differ at a single position: a tyrosine sits where the native phenylalanine would be. Tyrosine and phenylalanine are structurally almost identical apart from one hydroxyl group, and the added tyrosine provides a convenient site for radioiodination, which is useful in pharmacokinetic and tracer work.

The practical consequence is significant. Product listings labeled "HGH Fragment 176-191" very often quote a molecular weight near 1817, which corresponds to the tyrosine-containing hexadecapeptide rather than the native sequence. In other words, much of what circulates under the 176-191 label is specified as AOD-9604. Anyone evaluating this compound should read our dedicated AOD-9604 guide alongside this one, because that is where the actual study record lives. Claims made for "the fragment" are almost always extrapolations from AOD-9604 data.

The research lineage runs through Monash University in Melbourne, Australia. F. M. Ng and colleagues spent years dissecting the metabolic actions of human growth hormone, asking which structural domains were responsible for its effects on glucose and on lipid handling. That program produced a series of synthetic analogs modeled on the C-terminal region, of which AOD-9401 and later AOD-9604 are the best documented.

An early output of that work was published in 2000 in Hormone Research, where Ng and colleagues reported on the metabolic actions of a synthetic lipolytic domain of hGH in obese Zucker rats. The finding that shaped everything afterwards was the dissociation they described: adipose tissue from treated animals showed increased lipolytic activity, while, in contrast with chronic treatment using intact hGH, chronic treatment with the fragment showed no adverse effect on insulin sensitivity. The same year, in the American Journal of Physiology, Heffernan and colleagues reported that oral administration of the related analog AOD-9401 reduced lipogenic activity and increased lipolytic activity in adipose tissue, with corresponding effects observed in isolated adipose tissue from obese rodents and from humans.

The university work was commercialized through Metabolic Pharmaceuticals Ltd, an Australian company that took AOD-9604 forward as a candidate anti-obesity agent in the late 1990s and early 2000s. Notably, the clinical program pursued an oral formulation, not an injection, which is a detail frequently lost in contemporary discussion of the compound.

After the obesity program ended, the molecule did not disappear. It was repositioned in two directions: as a nutraceutical ingredient, and as a candidate for joint and cartilage applications, with intra-articular work published in a rabbit osteoarthritis model in 2015. The compound also attracted considerable public attention in Australia in 2013 during an investigation into supplement use in professional sport, which is part of why its name became widely known outside scientific circles.

So the fragment is not a new discovery. It is a molecule with roughly three decades of history, a completed early-phase clinical program, and no approval to show for it. That trajectory is itself an important piece of evidence.

Intact growth hormone promotes lipolysis, but it does so as part of a broad hormonal program. It binds the growth hormone receptor, triggers JAK-STAT signaling, drives hepatic IGF-1 output, and over time reduces insulin sensitivity. The proposed mechanism for the C-terminal fragment is that it reproduces the adipose tissue effect while bypassing the receptor-mediated program.

The receptor question was addressed directly in the preclinical work. In their 2001 report in the International Journal of Obesity, Heffernan and colleagues stated that AOD-9604 does not compete for the hGH receptor and does not induce cell proliferation, unlike hGH itself. That observation is the mechanistic basis for the claim that the fragment should not raise IGF-1, and the pooled human safety data later reported no effect on serum IGF-1 levels.

The positive mechanism is less settled. The most informative experiment is the one reported in Endocrinology in 2001, which examined the beta-3 adrenergic receptor (beta-3 AR), the main lipolytic receptor on fat cells. After 14 days of chronic intraperitoneal administration in obese mice, both hGH and AOD-9604 reduced body weight and body fat, and both raised the suppressed beta-3 AR RNA levels of obese mice toward the levels seen in lean animals. In beta-3 AR knockout mice, chronic treatment failed to produce the changes in body weight and lipolysis seen in wild-type controls. Yet in an acute experiment, AOD-9604 still increased energy expenditure and fat oxidation in those same knockout animals.

Read carefully, that pattern argues that the fragment is not simply a beta-3 agonist. The authors concluded that the lipolytic actions are not mediated directly through the beta-3 AR, although both compounds increase its expression, which may in turn contribute to enhanced lipolytic sensitivity over time. Acute and chronic effects appear to run through partly different routes.

Two caveats are worth stating plainly. First, this mechanistic picture was assembled in rodents and in isolated tissue, under experimental conditions with no established translation to human physiology. Second, demonstrating that a molecule can shift lipolysis markers is not the same as demonstrating that it changes body composition in people, a gap discussed in our overview of how peptides are studied for weight loss.

The preclinical record is the strongest part of the file, and it is reasonably consistent. Three studies carry most of the weight.

Obese Zucker rats (Ng et al., 2000). Adipose tissue from animals treated with the synthetic lipolytic domain showed increased lipolytic activity. The headline comparison was with intact hGH: chronic treatment with the fragment did not produce the deterioration in insulin sensitivity that chronic hGH did. This is the origin of the "fat loss without the growth hormone downside" framing.

Obese and lean mice (Heffernan et al., 2001, International Journal of Obesity). The study compared hGH and AOD-9604 in obese (ob/ob) and lean C57BL/6J mice, looking at body weight, energy balance and substrate oxidation. Both compounds significantly reduced body weight gain in the obese animals, associated with increased in vivo fat oxidation and increased plasma glycerol, an index of lipolysis. Unlike hGH, AOD-9604 did not induce hyperglycemia or reduce insulin secretion.

Beta-3 receptor knockout mice (Heffernan et al., 2001, Endocrinology). Fourteen days of intraperitoneal administration reduced body weight and body fat in obese mice and normalized beta-3 AR RNA expression, with the knockout experiments described in the previous section.

Outside metabolism, a 2015 study in Annals of Clinical and Laboratory Science examined intra-articular injection in a collagenase-induced knee osteoarthritis model in 32 New Zealand white rabbits. Weekly ultrasound-guided injections of saline, hyaluronic acid, AOD-9604, or AOD-9604 combined with hyaluronic acid were compared. The authors reported that AOD-9604 injections enhanced cartilage regeneration and that the combination was more effective than either hyaluronic acid or AOD-9604 alone.

These results are real, but they should be read for what they are. The metabolic studies used genetically obese rodent strains, injected administration, and treatment periods measured in days to a few weeks. Rodent adipose tissue is not human adipose tissue, and genetically obese mice are not a model of common human obesity. The osteoarthritis work is a single rabbit study in a different tissue with a different route of administration. None of this establishes an effect in people, and the human record, examined next, is where the story changes.

Unusually for a compound of this kind, there is a genuine human clinical record, and it is worth examining honestly in both directions.

In 2013, Stier, Vos and Kenley published a pooled analysis in the Journal of Endocrinology and Metabolism covering six randomized, double-blind, placebo-controlled trials conducted between 2001 and 2006 in approximately 900 healthy and clinically obese adults. The set included a seven-day multiple-dose study and two longer-term trials of chronic oral administration. The reported conclusions were that oral glucose tolerance testing showed no negative effect on carbohydrate metabolism, in contrast with hGH; that no anti-AOD-9604 antibodies were detected among the patients selected for antibody assay; that no withdrawal or serious adverse event related to intake occurred in any of the studies; and that the safety and tolerability profile was indistinguishable from placebo.

That is a meaningful amount of human exposure data for an unapproved peptide, and it is the single best argument its proponents have. But note carefully what the paper is: an analysis of safety and tolerability, authored by parties connected to the sponsor and published in a journal with limited indexing. It is not an efficacy demonstration, and it does not report a clinically meaningful weight-loss result.

The efficacy story is the part that is usually left out. The obesity development program was discontinued. AOD-9604 never advanced to phase 3, never obtained approval from the FDA, the EMA, the TGA or any comparable regulator, and no peer-reviewed publication reports a phase 2b trial result that supports continued development for obesity. The compound was subsequently repositioned toward nutraceutical and joint applications, which is not the trajectory of a molecule that had produced convincing fat-loss data. Readers should also note that detailed efficacy results from the later trials were not published in the peer-reviewed literature, which is itself a limitation on how confidently anyone can characterize them.

Finally, there is a gap specific to the subject of this guide. There is no published controlled human trial of the unmodified 176-191 sequence, and no published human efficacy trial of injected administration of either version that establishes meaningful fat loss. Marketing claims that cite "clinical studies" for injected HGH Fragment 176-191 are extrapolating from oral AOD-9604 safety data. Our survey of peptides studied for fat loss places this compound in context against molecules with far stronger human evidence.

No regulator has approved this fragment, or AOD-9604, as a medicine for any indication. It is not an FDA-approved drug, it holds no EMA marketing authorization, and it is not available as a licensed prescription product. Material offered for sale is typically labeled as a research chemical not for human consumption, and the legal position of purchase, possession and import varies substantially between jurisdictions.

In the United States, AOD-9604 has been examined specifically in the context of pharmacy compounding. In briefing material prepared for the Pharmacy Compounding Advisory Committee, the FDA described AOD-9604 as a hexadecapeptide consisting of hGH residues 177 to 191 with an additional N-terminal tyrosine and a disulfide bond between the two cysteines. The agency raised several concerns: the potential for immunogenicity when formulated as an injectable for subcutaneous administration, driven by aggregation potential and peptide-related impurities; difficulties in characterizing the active ingredient; and limited safety information. The substance was not added to the list of bulk drug substances permitted for compounding.

In sport, the position is unambiguous. Growth hormone, its fragments and its releasing factors fall under section S2 of the WADA Prohibited List, covering peptide hormones, growth factors, related substances and mimetics, and substances in that section are prohibited at all times, both in and out of competition. AOD-9604 and hGH 176-191 are named within the growth hormone fragment entry. Therapeutic use exemptions are not a realistic route for a substance with no approved indication.

Claims that the fragment is undetectable are false. Cox and colleagues published a detection and in vitro metabolism study in Drug Testing and Analysis in 2015, developing a urine method following solid-phase extraction and identifying metabolites formed after incubation in serum and urine, including a fragment consisting of the residues CRSVEGSCG that proved considerably more stable than the parent compound. Separately, analytical work has examined whether the molecule interferes with the WADA growth hormone isoform immunoassay, and seized preparations sold as AOD-9604 have been characterized in forensic casework.

Quality is a related and underappreciated issue. Peptides sold outside the regulated pharmaceutical supply chain have no guaranteed identity, purity, sterility or content. Our article on peptide safety considerations covers why that matters in practice, particularly for injectable material.

The honest answer is that the formal adverse event record is limited, mostly favorable, and mostly irrelevant to how the compound is actually used outside research settings.

Within the published clinical program, the pooled analysis of six placebo-controlled trials reported tolerability indistinguishable from placebo, with no serious adverse events related to intake, no detected anti-AOD-9604 antibodies among those tested, and no negative effect on carbohydrate metabolism on oral glucose tolerance testing. For a compound with this reputation, that record is reassuring as far as it goes.

It does not go very far, for four reasons. Those trials studied oral administration, while the material circulating today is almost always injected, and route of administration changes both the exposure profile and the immunogenicity risk. The trials ran for weeks to months, not years. They enrolled healthy or clinically obese adults, not people with significant comorbidities or on complex medication regimens. And the analysis was prepared by parties connected to the sponsor, which is a standard limitation but a real one.

Regulators have flagged concerns that the trials were not designed to detect. The FDA's compounding review specifically identified immunogenicity risk for injectable subcutaneous formulations arising from peptide aggregation and impurities, noted challenges in characterizing the substance, and referred to serious adverse events that may be associated with the substance while stating that causality is not clear. Those are manufacturing-and-formulation risks rather than intrinsic pharmacology risks, but for anyone using non-pharmaceutical material they are the more likely source of harm.

Practical risks associated with self-injection of unregulated peptides include injection site reactions, local infection, contamination with bacterial endotoxin, and exposure to incorrect or adulterated contents. Anecdotal reports circulating in online communities are not systematically collected, are not verified against the actual contents of what was injected, and cannot substitute for pharmacovigilance data.

Medical disclaimer: this section is educational and is not a safety assessment for personal use. HGH Fragment 176-191 is not approved for human use. Anyone considering any peptide should consult a qualified healthcare professional, and no information here should be used to self-treat.

Placing the fragment on the evidence ladder is the most useful thing a reader can take from this guide, because the gap between compounds in this space is enormous.

At the top sit the incretin-based agents. GLP-1 receptor agonists and dual agonists have large randomized phase 3 programs, regulatory approval for obesity in major jurisdictions, and published weight-loss results in the range of 15 to 22 percent of body weight depending on the agent and trial. Whatever one thinks of them, the evidentiary situation is not comparable.

In the middle sits tesamorelin, a growth hormone releasing factor analog with regulatory approval for a specific, narrow indication, namely excess visceral abdominal fat in HIV-associated lipodystrophy. It is instructive precisely because it shows what an approved peptide affecting adipose tissue looks like: a defined patient population, a defined endpoint, published phase 3 data, and a known monitoring requirement for IGF-1.

HGH Fragment 176-191 and AOD-9604 sit well below both. The honest summary is: a coherent mechanistic hypothesis, consistent rodent data, a credible but sponsor-run human safety record with no demonstrated efficacy, a discontinued obesity program, and no approval anywhere.

One claim deserves specific rebuttal: the fragment does not perform targeted or localized fat reduction. No published study supports site-specific fat loss in humans from this molecule, and systemic lipolysis does not work that way. For a broader comparison of the evidence behind this category, see our review of peptides studied for fat loss.

This article is for educational purposes only and is not medical advice. Consult a healthcare professional before considering any compound discussed here.